This is a relatively small study but I think it underscores the importance of screening for and treating depression during pregnancy. Previous studies have indicated that about 10% to 15% of women experience clinically significant [...]
Previous studies have shown that children who have lost a parent to suicide are more likely to attempt suicide than children whose parents died unintentionally. One obvious explanation for this finding is that the parents who attempt or commit suicide are more likely to have a mood disorder or serious psychiatric illness and that their children share this genetic vulnerability and are therefore more likely to have a psychiatric illness which increases their risk for suicide.
While many women complain of psychological distress during infertility treatment, it has been somewhat unclear if the anxiety and depression women may experience is related to having to undergo infertility treatment or to the hormonal agents that are used as part of the treatment, or a combination of the two.  While we know that changing levels of gonadal hormones, like estrogen, may affect mood and anxiety levels, we have very little information on the psychological effects of the hormone-modulating drugs used in assisted reproductive technology (ART).
Augmentation strategies can be used to optimize response in patients with major depressive disorder (MDD) who have not responded adequately to antidepressant monotherapy; however, we have no data on the use of adjunctive treatments in women with postpartum depression (PPD).  A recent study tested the effectiveness of antidepressant augmentation with aripiprazole (Abilify) in a cohort of 10 women with onset of a depression within 3 months of the birth of a healthy, close-to-term baby.
The Edinburgh Postnatal Depression Scale (EPDS) was modified by adding lifetime PND screening questions, assessing worst episode, and symptom timing of onset, in order to assess the lifetime prevalence of perinatal depression. Subjects from the [...]
Some, but not all, studies have demonstrated an increased risk of miscarriage among women who take antidepressants. However, it has been difficult to determine whether this increased risk was related to exposure to the medication [...]
We have received many emails and calls from colleagues and patients regarding the recent article on the safety of SSRI use during pregnancy published in the New York Times. In this article, health writer Roni Caryn Rabin, detailed the risks associated with the use of antidepressants during pregnancy.
Women with histories of major depression are vulnerable during the transition to menopause and are at increased risk for relapse; however, we have less information on how this transition affects women with bipolar disorder.
Posttraumatic stress disorder (PTSD) is relatively common among pregnant and postpartum women. The lifetime prevalence of PTSD for women is about 10%, with one-third of episodes lasting more than five years. Given the relatively high [...]
This week in the New York Times, there is a two-part story on maternal mental illness. Highlighting the experience of two women who became ill during the postpartum period, the articles focus on the range of disorders which can emerge during the postpartum period -- not only depression, but bipolar disorder, anxiety, OCD, and psychosis.
